
    
      The primary objective of this study is to compare time to symptomatic progression (TTSP) from
      study entry in asymptomatic patients with RAI-refractory progressive DTC for whom there is a
      decision to initiate MKIs at study entry with that of asymptomatic patients with
      RAI-refractory progressive DTC for whom there is a decision to not initiate MKIs at study
      entry.
    
  